hit counter

Vraylar (Cariprazine) Approved For Schizophrenia & Bipolar Disorder

Vraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder.  In clinical trials, the drug was referenced as “RGH-188” – containing Cariprazine as the primary active ingredient.  The drug had completed Phase III clinical trials in 2012, and was pending FDA approval for …

Read more

3 New Bipolar Medications (2015): Drugs In Clinical Trials

Bipolar disorder is a condition characterized by cyclical mood swings, transitioning from depression to mania (or hypomania).  For a period of time, an individual with bipolar disorder will experience debilitating bouts of depression – and often unexpectedly, their entire neurophysiology will shift to facilitate a state of mania (elevated mood).  Diagnostically, there are multiple types …

Read more

20+ New Schizophrenia Medications In Development (2015)

It is estimated that over 2.5 million adults in the United States have been diagnosed with schizophrenia; this equates to approximately 1.1% of the population.  There are many different types of schizophrenia, in fact, genetic clusters suggest it is 8 distinct diseases.  Therefore not everyone diagnosed with schizophrenia has the same set of symptoms. Certain …

Read more

Invega (Paliperidone) & Weight Gain: What Should You Expect?

Invega (Paliperidone) is considered a newer spin-off of the antipsychotic Risperdal in that it contains the same active metabolite, but is thought to have fewer side effects and drug interactions.  It was initially approved in 2006 for the treatment of schizophrenia and was since granted approval for the treatment of schizoaffective disorder in 2009.  While …

Read more

Invega (Paliperidone) Withdrawal Symptoms: List of Possibilities

Invega (Paliperidone) is an atypical antipsychotic approved in 2006 for the treatment of schizophrenia.  Several years later in 2009, a longer-acting format of the medication called “Invega Sustenna” was also approved.  Invega Sustenna is an injectable form of the drug that is administered every 4 weeks and is thought to be advantageous it mitigates risk …

Read more

Fanapt (Iloperidone) & Weight Gain: What Should You Expect?

Fanapt (Iloperidone) is an antipsychotic that was approved in 2009 for the treatment of schizophrenia.  It functions similar to most current-market atypical antipsychotics in that it acts as an antagonist of the 5-HT2A receptor and D2 dopamine receptor.  It is thought to produce fewer extrapyramidal side effects (e.g. akathisia) compared to other antipsychotics. The drug …

Read more